Initial remission duration of less than 1 year is no longer an adverse prognostic factor for patients with relapsed HL undergoing high dose therapy and autologous stem cell transplant: Results of a combined analysis from two large transplant centers Meeting Abstract

  

Authors:	Moskowitz, A. J.; Sweetenham, J.; Bolwell, B. J.; Maragulia, J. C.; Vanak, J. M.; Moskowitz, C. H.; Smith, S.
Abstract Title:	Initial remission duration of less than 1 year is no longer an adverse prognostic factor for patients with relapsed HL undergoing high dose therapy and autologous stem cell transplant: Results of a combined analysis from two large transplant centers
Meeting Title:	51st Annual Meeting of the American Society of Hematology (ASH)
Journal Title:	Blood
Volume:	114
Issue:	22
Meeting Dates:	2009 Dec 5-8
Meeting Location:	New Orleans, LA
ISSN:	0006-4971
Publisher:	American Society of Hematology
Date Published:	2009-11-20
Start Page:	1325
End Page:	1326
Language:	English
ACCESSION:	WOS:000272725804078
PROVIDER:	wos
PUBMED:	22276299
DOI:	10.1182/blood.V114.22.3413.3413
Notes:	Meeting Abstract: 3413 -- Source: Wos

https://synapse.mskcc.org/synapse/works/has_related_data_chk/127447